Asset
FOSIFLOXURIDINE NAFALBENAMIDE
NUCANA PLC AMERICAN DEPOSITARY SHARE
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03428958 | phase1_2 | completed | 2018-10-05 | 2024-03-19 | NuCana plc | A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment |
| NCT05678257 | phase2 | terminated | 2023-04-18 | 2024-08-29 | NuCana plc | A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer |
| NCT05714553 | phase1_2 | terminated | 2023-03-08 | 2025-05-30 | NuCana plc | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours |
FDA applications (0)
This company has no applications containing this asset.